| systematic review | Q1504425 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/14737167.2017.1305891 |
| P698 | PubMed publication ID | 28283002 |
| P50 | author | Ioannis Petrakis | Q118907122 |
| Kostas Athanasakis | Q118907146 | ||
| P2093 | author name string | Alexandros Ginis | |
| Ilias J Kyriopoulos | |||
| P2860 | cites work | Cost of managing complications resulting from type 2 diabetes mellitus in Canada | Q24793101 |
| The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data | Q31031964 | ||
| Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study | Q31164723 | ||
| The costs of diabetic foot: the economic case for the limb salvage team | Q33678478 | ||
| A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. I: prevention | Q33765639 | ||
| A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. II: treatment | Q33788802 | ||
| Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review | Q34016162 | ||
| The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial | Q34203046 | ||
| Kelly West Lecture 1991. Challenges in diabetes epidemiology--from West to the rest | Q35914322 | ||
| Preventing foot ulcers in patients with diabetes | Q36006260 | ||
| A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. | Q36440640 | ||
| Geographic variation in Medicare spending and mortality for diabetic patients with foot ulcers and amputations | Q36905132 | ||
| Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. | Q37133401 | ||
| The economic impact of hospitalization for diabetic foot infections in a Caribbean nation | Q37632498 | ||
| Diabetic foot infections: current concept review | Q38009319 | ||
| Declines in lower extremity amputation in the US Medicare population, 2000-2010. | Q38079568 | ||
| Systematic Reviews and Meta-analysis: Understanding the Best Evidence in Primary Healthcare | Q38183404 | ||
| Clinical and economic assessment of diabetic foot ulcer debridement with collagenase: results of a randomized controlled study | Q38442618 | ||
| Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. | Q39929915 | ||
| Clinical characteristics and medical costs in patients with diabetic amputation and nondiabetic patients with nonacute amputation in central urban hospitals in China | Q40179497 | ||
| Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers | Q41158273 | ||
| Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products | Q41236010 | ||
| Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers | Q41961409 | ||
| An antibiotic formulary for a tertiary care foot clinic: admission avoidance using intramuscular antibiotics for borderline foot infections in people with diabetes. | Q42283898 | ||
| Impact of diabetes on costs before and after major lower extremity amputations in Germany. | Q43531779 | ||
| Economic analysis of soft-heel casting for diabetic foot ulcer: prevention and treatment | Q43561130 | ||
| Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes | Q43903130 | ||
| Beneficial effects of implementing guidelines on microbiology and costs of infected diabetic foot ulcers | Q44238920 | ||
| Economic evaluation of Vacuum Assisted Closure® Therapy for the treatment of diabetic foot ulcers in France | Q44662796 | ||
| Cost comparison: limb salvage versus amputation in diabetic patients with charcot foot | Q44815701 | ||
| A cost analysis of diabetic lower-extremity ulcers | Q44875707 | ||
| A staged management diabetes foot program versus standard care: a 1-year cost and utilization comparison in a state public hospital system | Q44997077 | ||
| An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers | Q46622818 | ||
| An assessment of the disease burden of foot ulcers in patients with diabetes mellitus attending a teaching hospital in Lagos, Nigeria. | Q46765505 | ||
| An economic evaluation of VAC therapy compared with wound dressings in the treatment of diabetic foot ulcers | Q47793526 | ||
| Resource utilization and economic costs of care based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabetic foot wounds. | Q47828867 | ||
| A multidisciplinary diabetic foot protocol at Chiang Mai University Hospital: cost and quality of life | Q49066677 | ||
| Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium. | Q50664197 | ||
| The health care costs of diabetic peripheral neuropathy in the US. | Q50719755 | ||
| The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002--results from the Diabetic Microvascular Complications (DIMICO) study. | Q51119009 | ||
| Cost-effectiveness analysis of medical intervention in patients with early detection of diabetic foot in a tertiary care hospital in Bangladesh. | Q51128913 | ||
| Predicted annual costs for inpatients with diabetes and foot ulcers in a developing country-a simulation of the current situation in Brazil. | Q51141109 | ||
| Burden of diabetic foot ulcers for medicare and private insurers. | Q51229127 | ||
| Cost of diabetic foot disease to the National Health Service in England. | Q51250357 | ||
| Comparative effectiveness of the SNaP™ Wound Care System. | Q51594908 | ||
| The cost effectiveness of Apligraf treatment of diabetic foot ulcers. | Q51803919 | ||
| Five steps to conducting a systematic review. | Q52021539 | ||
| Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. | Q53291347 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 165-180 | |
| P577 | publication date | 2017-03-10 | |
| P1433 | published in | Expert Review of Pharmacoeconomics & Outcomes Research | Q15734522 |
| P1476 | title | Losing a foot versus losing a dollar; a systematic review of cost studies in diabetic foot complications | |
| P478 | volume | 17 |
| Q50128521 | Antibiotic Resistance in Diabetic Foot Soft Tissue Infections: A Series From Greece |
| Q47139557 | Chronic Osteomyelitis Increases the Incidence of Type 2 Diabetes in Humans and Mice |
| Q91938151 | Interim Results of the Remede d'Or Study: A Multicenter, Single-Blind, Randomized, Controlled Trial to Assess the Safety and Efficacy of an Innovative Topical Formulation of Erythropoietin for Treating Diabetic Foot Ulcers |
| Q47185941 | Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial |
| Q90721805 | The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial |
Search more.